Table 1 Characteristics of patients in irAE and non-irAE groups
| Â | Total No. (%) | non-irAE No. (%) | irAE No. (%) | p-value |
|---|---|---|---|---|
Total N | 74 | 50 | 24 | Â |
Gender | ||||
 female | 23 (31.1) | 12 (24.0) | 11 (45.8) | 0.067 |
 male | 51 (68.9) | 38 (76.0) | 13 (54.2) |  |
Age | ||||
  < 65 | 41 (55.4) | 26 (52.0) | 15 (62.5) | 0.460 |
  ≥ 65 | 33 (44.6) | 24 (48.0) | 9 (37.5) |  |
ECOG PS | ||||
 0 | 11 (14.9) | 5 (10.0) | 6 (25.0) | 0.159 |
  ≥ 1 | 63 (85.1) | 45 (90.0) | 18 (75.0) |  |
Treatment Line | ||||
 1–2 | 25 (33.8) | 12 (24.0) | 13 (54.2) | 0.017 |
 3–4 | 49 (66.2) | 38 (76.0) | 11 (45.8) |  |
Number of Metastatic Sites | ||||
  < 2 | 66 (89.2) | 46 (92.0) | 20 (83.3) | 0.424 |
  ≥ 2 | 8 (10.8) | 4 (8.0) | 4 (16.7) |  |
Histologic Type | ||||
 non-adenocarcinoma | 5 (6.8) | 3 (6.0) | 2 (8.3) | 0.657 |
 adenocarcinoma | 69 (93.2) | 47 (94.0) | 22 (91.7) |  |
HER2 Status | ||||
 negative | 66 (89.2) | 44 (88.0) | 22 (91.7) | 1.000 |
 positive | 8 (10.8) | 6 (12.0) | 2 (8.3) |  |
Disease Status | ||||
 stage III | 29 (39.2) | 20 (40.0) | 9 (37.5) | 0.757 |
 Stage IV | 33 (44.6) | 23 (46.0) | 10 (41.7) |  |
 recurrence | 12 (16.2) | 7 (14.0) | 5 (20.8) |  |
ALP | ||||
 low | 41 (55.4) | 27 (54.0) | 14 (58.3) | 0.805 |
 high | 33 (44.6) | 23 (46.0) | 10 (41.7) |  |
NLR | ||||
 low (< 4) | 49 (66.2) | 38 (76.0) | 11 (45.8) | 0.017 |
 high (≥ 4) | 25 (33.8) | 12 (24.0) | 13 (54.2) |  |
Clinical Baseline Value (Median (IQR)) | ||||
 WBC | 5.82 (4.17, 7.20) | 5.62 (4.17, 6.56) | 6.56 (4.23, 8.00) | 0.145 |
 Neutrophil | 3.45 (3.09, 5.13) | 3.45 (3.09, 5.03) | 5.03 (2.81, 6.72) | 0.282 |
 Lymphocyte | 0.88 (0.75, 1.34) | 1.01 (0.84, 1.76) | 0.85 (0.74, 0.96) | 0.049 |
 NLR | 3.77 (2.57, 4.98) | 3.68 (2.57, 3.93) | 4.98 (3.26, 7.56) | 0.081 |
 Plt | 188.00 (135.25, 257.50) | 196.50 (90.00, 262.00) | 188.00 (148.00, 234.00) | 0.826 |
 Hemoglobin | 109.00 (101.00, 124.28) | 114.00 (107.50, 131.68) | 92.00 (76.00, 103.00) | 0.001 |